The company intends to use the funds to support the continued advancement of its pipeline including its lead program, VGA039, a monoclonal antibody that targets Protein S to restore balance in blood clotting.

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

201 Haskins Way, 5th Floor South
San Francisco, CA 94080
USA

Phone

888-742-1338

Website

www.star-therapeutics.com

Email Address

[email protected]

Overview

Our mission is to develop life-changing therapies for as many rare diseases as possible for the millions of patients in urgent need. Medical science has identified approximately 7,000 rare diseases. Individually, these conditions may impact few patients. Together, however, they affect approximately 30 million patients in the US alone, and 300 million worldwide.1-3 Although these diseases affect so many, only about 650 FDA-approved treatments have been developed to target them.

Profile

Social Media

Star Therapeutics Company Twitter Account

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Adam Rosenthal

Chief Marketing Officer

Gary Patou

Chief Operating Officer

Kathy Dong

Chief Scientific Officer

Sandip Panicker

Browse more venture capital transactions:

Prev: 10/1/2025: Phaidra venture capital transaction
Next: 10/1/2025: Temporal venture capital transaction

Share this article

About Our Venture Capital Transactions Database

Our team works diligently to report on every notable VC transaction. All VC database entries reported here are sourced from company press releases and news coverage. The information is sourced from VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary